| For: | Ma J, Wang FY, Tang XD. Involvement of the NLRP3/IL-1β pathway in activation and effector functions of γδT17 cells in patients with ulcerative colitis. World J Gastroenterol 2025; 31(12): 98174 [PMID: 40182600 DOI: 10.3748/wjg.v31.i12.98174] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v31/i12/98174.htm |
| Number | Citing Articles |
| 1 |
Jiaying Chen, Erxin Zhang, Xuantao Qian, Xiaoqing Shang, Jie Yu, Jiheng Luo, Weiwei Hao. Progress in the Treatment of Ulcerative Colitis by Targeting NLRP3 Inflammasome. Drug Design, Development and Therapy 2026; doi: 10.2147/DDDT.S611506
|
| 2 |
Qin Qin, Qingjun Dong, Yan Pan, Chen Wang, Jingen Lu. Hongyuyin attenuates intestinal fibrosis in ulcerative colitis in mice revealed by transcriptomic and network pharmacology analyses. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-06021-w
|
| 3 |
Wei-Wei Dong, Tao Liu, Li-Xia He, Wen-Ting He. Targeting pyroptosis in inflammatory bowel disease: A potentially effective therapeutic approach. World Journal of Gastroenterology 2025; 31(43): 111358 doi: 10.3748/wjg.v31.i43.111358
|
| 4 |
Ting Yang, Min Feng, Hui Yin, Jian-Hua Wan, Yong-Hong Liang, Xiao Zhang, Chang Peng, Tao Yang, Ming Yang, Hai-Yan Zhang. 1,2,4-trimethoxybenzene exerts multi-target effects against ulcerative colitis by inhibiting the NLRP3 inflammasome and remodeling the gut microbiota-metabolism axis. European Journal of Pharmacology 2026; 1029 doi: 10.1016/j.ejphar.2026.179059
|